Abstract
The metabolic syndrome is an emerging global epidemic characterized by clustering of metabolic abnormalities leading to increased cardiovascular risk: glucose intolerance or type 2 diabetes, dyslipidemia, hypertension, and “central” obesity. Scientists are decoding and piecing together the molecular texture underlying the metabolic syndrome: insulin resistance and dyslipidemia stand out as central pathophysiological events. In this picture, the liver rises as the leading organ in the maintenance of metabolic fitness; it serves as the first relay station for processing dietary information, and encloses the whole biochemical machinery for both glucose and lipid storage and disposal. In addition, the liver is a target of the different endocrine molecules secreted by pancreatic β-cells and adipose tissue. Evidence collected in animal models supports the central role of the liver in the metabolic syndrome. While specific bereft of insulin sensitivity in skeletal muscle and adipose tissue fails to induce diabetes at certain extent, this is constantly the outcome in case of hepatic insulin resistance. Also, dyslipidemia is currently interpreted as the result of increased flux of free fatty acids to the liver with ensuing misbalance of lipoprotein synthesis and removal. In this review we bring together recent advances in the field of lipid sensing nuclear receptors, adipokines and other molecules responsible for metabolic fitness, and provide a putative coherent frame to conceive the pathophysiology of the metabolic syndrome.
Keywords: Metabolic syndrome, liver, nuclear receptors, adipokines, mouse models, gene therapy
Current Pharmaceutical Design
Title: Targeting the Liver in the Metabolic Syndrome: Evidence from Animal Models
Volume: 13 Issue: 21
Author(s): Michele Petruzzelli, Giuseppe Lo Sasso, Piero Portincasa, Giuseppe Palasciano and Antonio Moschetta
Affiliation:
Keywords: Metabolic syndrome, liver, nuclear receptors, adipokines, mouse models, gene therapy
Abstract: The metabolic syndrome is an emerging global epidemic characterized by clustering of metabolic abnormalities leading to increased cardiovascular risk: glucose intolerance or type 2 diabetes, dyslipidemia, hypertension, and “central” obesity. Scientists are decoding and piecing together the molecular texture underlying the metabolic syndrome: insulin resistance and dyslipidemia stand out as central pathophysiological events. In this picture, the liver rises as the leading organ in the maintenance of metabolic fitness; it serves as the first relay station for processing dietary information, and encloses the whole biochemical machinery for both glucose and lipid storage and disposal. In addition, the liver is a target of the different endocrine molecules secreted by pancreatic β-cells and adipose tissue. Evidence collected in animal models supports the central role of the liver in the metabolic syndrome. While specific bereft of insulin sensitivity in skeletal muscle and adipose tissue fails to induce diabetes at certain extent, this is constantly the outcome in case of hepatic insulin resistance. Also, dyslipidemia is currently interpreted as the result of increased flux of free fatty acids to the liver with ensuing misbalance of lipoprotein synthesis and removal. In this review we bring together recent advances in the field of lipid sensing nuclear receptors, adipokines and other molecules responsible for metabolic fitness, and provide a putative coherent frame to conceive the pathophysiology of the metabolic syndrome.
Export Options
About this article
Cite this article as:
Michele Petruzzelli , Giuseppe Lo Sasso , Piero Portincasa , Giuseppe Palasciano and Antonio Moschetta , Targeting the Liver in the Metabolic Syndrome: Evidence from Animal Models, Current Pharmaceutical Design 2007; 13 (21) . https://dx.doi.org/10.2174/138161207781039625
DOI https://dx.doi.org/10.2174/138161207781039625 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Endothelial Nitric Oxide Synthase in Pathophysiological Conditions
Cardiovascular & Hematological Disorders-Drug Targets Formulation of Gastric Floating System Using Bio-Sourced Terminalia Catappa Gum and in vivo Evaluation
Current Drug Delivery MicroRNA-136 Promotes Vascular Muscle Cell Proliferation Through the ERK1/2 Pathway by Targeting PPP2R2A in Atherosclerosis
Current Vascular Pharmacology Homocysteine: A Risk Factor in Patietns with Cardiovascular Disorders in Pakistan
Current Bioactive Compounds Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design Effects of Vitamin E and C on Placental Oxidative Stress: An In Vitro Evidence for the Potential Therapeutic or Prophylactic Treatment of Preeclampsia
Medicinal Chemistry Pulmonary Hypertension in Cardiac Surgery
Current Cardiology Reviews The APOE Genotype: Modification of Therapeutic Responses in Alzheimer's Disease
Current Pharmaceutical Design Myogenic Properties of Brain and Cardiac Vessels and their Relation to Disease
Current Vascular Pharmacology Preface: EDITORIAL COMMENT “Perfect 24-hr Blood Pressure Control” From Morning to Nocturnal Hypertension: Up-To-Date 2015
Current Hypertension Reviews Current Therapy in Sarcoidosis, the Role of Existing Drugs and Future Medicine
Inflammation & Allergy - Drug Targets (Discontinued) Perioperative Management of Patients with Down Syndrome
Current Pediatric Reviews Inducible Nitric Oxide Synthase as a Possible Target in Hypertension
Current Drug Targets Cardiovascular Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine Pharmacotherapy and Prevention of Vascular Dementia
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic:Central Hemodynamics and Arterial Stiffness: Methodological, Clinical and Pharmaceutical Considerations(Executive Editor: Theodore G. Papaioannou)]
Current Pharmaceutical Design Protein Kinase C – Possible Therapeutic Target to Treat Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy Effect of Cardiovascular Injury on Catabolism of Adenosine and Adenosine 5-‘Triphosphate in Systemic Blood in a Freely Moving Rat Model In Vivo
Drug Metabolism Letters Passive Smoking and Coronary Heart Disease
Current Vascular Pharmacology